Table 2 Standardized incidence ratio (SIR) of breast cancer among women with AIDS

From: Risk of breast, ovary, and uterine corpus cancers among 85 268 women with AIDS

 

Breast cancer cases

  
 

Observed

Expected

SIR

95% CI

Matches by social security number a

 High (84%)

111

150.4

0.74

0.61–0.89

 Medium (70%)

149

225.6

0.66

0.56–0.78

 Low (25%)

53

77.1

0.69

0.51–0.90

Cancer stage b

 Local

37

75.6

0.49

0.34–0.68

 Regional

34

55.4

0.61

0.42–0.86

 Distant

9

10.2

0.89

0.40–1.68

 Missing/unknown

7

8.7

0.81

0.32–1.66

AIDS-relative time (months) c

 −60 to –25

64

119.9

0.53

0.41–0.68

 −24 to −7

83

84.1

0.99

0.79–1.22

 −6 to +3

56

48.5

1.15d

0.87–1.50

 +4 to +27

47

81.1

0.58

0.43–0.77

 +28 to +60

40

70.5

0.57

0.41–0.77

 +61 to +120

23

49.2

0.47

0.30–0.70

 

Ptrend 0.14

 

CD4 count e

 0–99 cells μl−1

24

44.7

0.54

0.34–0.80

 100–199 cells μl−1

31

51.5

0.60

0.41–0.85

 ⩾200 cells μl−1

12

17.4

0.69

0.35–1.21

 

Ptrend 0.47

 

AIDS onset yearf

    

 1980–1989

0

4.7

0

0–0.78

 1990–1995

14

36.7

0.38

0.21–0.64

 1996–2002

33

39.6

0.83

0.57–1.17

 

Ptrend 0.002

 
  1. aFour registries in ‘high’, three in ‘medium, five in ‘low’. Excludes rural Georgia, which had no matched breast cancer cases.
  2. bCancer risk by stage during +4 to +60 months after AIDS onset. One registry with miscoded stage data excluded.
  3. cAIDS-relative time intervals are: distant pre-AIDS (−60 to −25), later pre-AIDS (−24 to −7), at AIDS onset (−6 to +3, excluded from trend test), shortly after AIDS onset (+4 to +27), later after AIDS onset (+28 to +60), and very late after AIDS onset (+61 to +120).
  4. dPtrend for AIDS-relative time excludes the AIDS onset period (−6 to +3 months).
  5. eObserved and expected cases and SIR presented are for +4 to +60 months by CD4 count at AIDS (within −6 to +3 months of AIDS onset). Results for breast cancer were similar during +4 to +27 months (Ptrend=0.63) and +28 to +60 months (Ptrend=0.58).
  6. fObserved and expected cases and SIR presented are for +4 to +27 months by cohort of AIDS onset: little or no antiretroviral therapy (1980–1989), availability of single and dual nucleoside reverse transcriptase inhibitors (1990–1995), and availability of highly active antiretroviral therapy (HAART) combinations (1996–2002). Breast cancer trend by calendar year of AIDS onset was similar in two sensitivity analyses. For one, cases occurring in the +4 to +60 post-AIDS interval were used (Ptrend=0.01). For the second, using the +4 to +27 post-AIDS interval, AIDS-onset years were divided as 1980–1986, 1987–1995, and 1996–2002 (Ptrend=0.006).
Back to article page